ViGenCell’s Immune Cell Therapies To Get A Boost From $85M IPO
IPO Priced At Top Of Stock Price Band
Executive Summary
Korean bioventure ViGenCell successfully completes an IPO on the Kosdaq market with strong subscription rates from investors, reflecting the continued keen interest in biopharma shares in South Korea this year.
You may also be interested in...
South Korea's HK inno.N Targets Cell Therapy, Vaccine Expansion Following $500m IPO
South Korean pharma HK inno.N’s $500m IPO has drawn strong interest with subscriptions from institutional investors marking a record high. The IPO should help it speed up development of cell and gene therapies and beef up its vaccines business.
Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
Korea's AriBio Progresses Phase III Program For Oral Alzheimer's Contender
South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.